Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 136

Results For "IMI"

4120 News Found

GSK’s RSV vaccine ‘Arexvy’ receives positive European Medicines Agency’s  CHMP opinion for adults aged 50-59
Drug Approval | July 30, 2024

GSK’s RSV vaccine ‘Arexvy’ receives positive European Medicines Agency’s CHMP opinion for adults aged 50-59

Decision on EU marketing authorisation for this population expected by September 2024


Pfizer Ltd. posts Q1 FY25 PAT at Rs. 150.71 Cr
News | July 30, 2024

Pfizer Ltd. posts Q1 FY25 PAT at Rs. 150.71 Cr

Pfizer Ltd. has reported total income of Rs. 604.70 crores during the period ended June 30, 2024


Dr Reddys Laboratories posts Q1 FY25 consolidated PAT at Rs. 1,392 Cr
News | July 29, 2024

Dr Reddys Laboratories posts Q1 FY25 consolidated PAT at Rs. 1,392 Cr

Dr. Reddy's Laboratories has reported total income of Rs. 7,672.7 crores during the period ended June 30, 2024


USAID and Takeda launch dengue prevention campaign
Public Health | July 27, 2024

USAID and Takeda launch dengue prevention campaign

Campaign launched to spread awareness regarding dengue prevention and control


Mankind Pharma to acquire 100% stake in Bharat Serums from Advent for Rs. 13,630 Cr
News | July 26, 2024

Mankind Pharma to acquire 100% stake in Bharat Serums from Advent for Rs. 13,630 Cr

Acquisition in line with Mankind’s stated objective to expand its presence in high entry barrier complex portfolios and high potential OTX brands


Emcure Pharmaceuticals signs PPA with Sunsure Energy for solar power
News | July 26, 2024

Emcure Pharmaceuticals signs PPA with Sunsure Energy for solar power

The partnership will significantly advance their sustainability initiatives by meeting around 67% of their power requirements for these plants


USFDA inspects Gland Pharma’s Dundigal facility
Drug Approval | July 26, 2024

USFDA inspects Gland Pharma’s Dundigal facility

The inspection was concluded with two 483 observations


European Commission approves Pfizer’s Durveqtix gene therapy for adults with hemophilia B
Drug Approval | July 26, 2024

European Commission approves Pfizer’s Durveqtix gene therapy for adults with hemophilia B

A one-time dose of DURVEQTIX has reduced bleeds post-treatment compared to standard of care with a median annualized bleed rate (ABR) of zero bleeds (range 0 to 9.9)


Cupid widens e-Commerce presence on leading Indian platforms
News | July 26, 2024

Cupid widens e-Commerce presence on leading Indian platforms

This strategic move aims to make Cupid's high-quality products more accessible to consumers nationwide